Stein Steven H, an insider at Incyte Corp (INCY), sold 102,886 shares of the company on November 4, 2025, at a price of $102.20 per share, bringing the total transaction value to $10.51 million. Following this sale, he retains an equal number of shares in the biotechnology firm, which specializes in the discovery and development of proprietary therapeutics.
Incyte Corp, headquartered in Wilmington, Delaware, operates in two therapeutic areas: Hematology/Oncology and Inflammation and Autoimmunity. The company’s hematology and oncology franchise includes six products, such as JAKAFI (ruxolitinib) and MONJUVI (tafasitamab-cxix), alongside numerous clinical development programs. With a market capitalization of $20.5 billion, Incyte has a trailing P/E ratio of 17.24 and an EPS of 5.91.
The move underscores the complexity of insider transactions, which can arise from various motivations, including diversification or personal financial needs. While significant selling activity can attract investor attention, it does not inherently signal negative sentiment toward the company.
Investors are encouraged to consider insider transactions as part of a broader analysis, examining patterns across multiple insiders and time periods. Such decisions reflect the need for a comprehensive view when assessing market signals.
Incyte is set to report its upcoming earnings on April 26, 2026, with an estimated EPS of $1.63 and revenue of $1.3 billion, followed by another report on July 26, 2026, where EPS is expected to be $1.68 with the same revenue forecast.